Abdellah Hassani-Allali
101 College Street
Toronto, ON M5G1L7, Canada
Toronto, ON M5G1L7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor.
Journal: Journal of medicinal chemistry
Published: January 08, 2025
Development of HC-258, a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration.
Journal: ACS medicinal chemistry letters
Published: September 06, 2023
Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.
Journal: Bioorganic & medicinal chemistry letters
Published: August 04, 2023
Enzymatic nucleosome acetylation selectively affects activity of histone methyltransferases in vitro.
Journal: Biochimica et biophysica acta. Gene regulatory mechanisms
Published: February 10, 2022
Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.
Journal: ChemMedChem
Published: June 15, 2021
Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
Journal: Journal of medicinal chemistry
Published: February 01, 2021
A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
Journal: Nature chemical biology
Published: July 10, 2020
Remodelin Is a Cryptic Assay Interference Chemotype That Does Not Inhibit NAT10-Dependent Cytidine Acetylation.
Journal: ACS medicinal chemistry letters
Published: April 14, 2020
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function.
Journal: Journal of medicinal chemistry
Published: September 25, 2019
Identification and characterization of the first fragment hits for SETDB1 Tudor domain.
Journal: Bioorganic & medicinal chemistry
Published: May 24, 2019
Last Updated: 09/26/2026